Cogent Biosciences presents new preclinical data on ErbB2, PI3Kalpha programs

Cogent Biosciences presented updated preclinical data from its potent, selective and brain penetrant ErbB2 inhibitor program along with initial preclinical data from its newly disclosed H1047R mutant-selective PI3Kalpha inhibitor discovery program at the 2023 San Antonio Breast Cancer Symposium, taking place December 5-9, 2023 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. “Broadening our pipeline of potential best-in-class targeted therapies remains key to our long-term strategy, and we are excited to provide an update on our selective, EGFR-sparing ErbB2 inhibitor, which features exceptional potency, half-life and oral bioavailability with potentially best-in-class brain penetrance to enable inhibition of mutations in CNS tissue,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “In addition, we are pleased to present initial data on our effort to design a potent H1047R mutant-selective PI3Kalpha inhibitor. This program aligns with our mission of creating best-in-class targeted therapies for patients with genetically defined diseases and is complementary to our efforts focused on the development of bezuclastinib in advanced and nonadvanced systemic mastocytosis and GIST.”